UTHR Annual Accounts Receivable
$278.90 M
+$58.50 M+26.54%
31 December 2023
Summary:
As of January 22, 2025, UTHR annual accounts receivable is $278.90 million, with the most recent change of +$58.50 million (+26.54%) on December 31, 2023. During the last 3 years, it has risen by +$121.50 million (+77.19%). UTHR annual accounts receivable is now -6.13% below its all-time high of $297.10 million, reached on December 31, 2017.UTHR Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
UTHR Quarterly Accounts Receivable
$341.80 M
+$51.10 M+17.58%
30 September 2024
Summary:
As of January 22, 2025, UTHR quarterly accounts receivable is $341.80 million, with the most recent change of +$51.10 million (+17.58%) on September 30, 2024. Over the past year, it has increased by +$83.20 million (+32.17%). UTHR quarterly accounts receivable is now at all-time high.UTHR Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
UTHR Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +26.5% | +32.2% |
| 3 y3 years | +77.2% | +32.2% |
| 5 y5 years | +58.7% | +128.5% |
UTHR Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +40.4% | at high | +154.1% |
| 5 y | 5-year | at high | +84.2% | at high | +154.1% |
| alltime | all time | -6.1% | >+9999.0% | at high | >+9999.0% |
United Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $341.80 M(+17.6%) |
| June 2024 | - | $290.70 M(-5.4%) |
| Mar 2024 | - | $307.30 M(+10.2%) |
| Dec 2023 | $278.90 M(+26.5%) | $278.90 M(+7.8%) |
| Sept 2023 | - | $258.60 M(-5.2%) |
| June 2023 | - | $272.70 M(+102.8%) |
| Mar 2023 | - | $134.50 M(-39.0%) |
| Dec 2022 | $220.40 M(+10.9%) | $220.40 M(-4.9%) |
| Sept 2022 | - | $231.70 M(+33.6%) |
| June 2022 | - | $173.40 M(+1.7%) |
| Mar 2022 | - | $170.50 M(-14.2%) |
| Dec 2021 | $198.70 M(+26.2%) | $198.70 M(-6.6%) |
| Sept 2021 | - | $212.80 M(+22.7%) |
| June 2021 | - | $173.40 M(+22.9%) |
| Mar 2021 | - | $141.10 M(-10.4%) |
| Dec 2020 | $157.40 M(+4.0%) | $157.40 M(+3.3%) |
| Sept 2020 | - | $152.30 M(-11.5%) |
| June 2020 | - | $172.00 M(+15.0%) |
| Mar 2020 | - | $149.60 M(-1.2%) |
| Dec 2019 | $151.40 M(-13.8%) | $151.40 M(-17.5%) |
| Sept 2019 | - | $183.60 M(+1.4%) |
| June 2019 | - | $181.00 M(+13.3%) |
| Mar 2019 | - | $159.80 M(-9.0%) |
| Dec 2018 | $175.70 M(-40.9%) | $175.70 M(-18.4%) |
| Sept 2018 | - | $215.20 M(-14.4%) |
| June 2018 | - | $251.30 M(+19.0%) |
| Mar 2018 | - | $211.10 M(-28.9%) |
| Dec 2017 | $297.10 M(+38.5%) | $297.10 M(+18.0%) |
| Sept 2017 | - | $251.80 M(-8.1%) |
| June 2017 | - | $273.90 M(+45.7%) |
| Mar 2017 | - | $188.00 M(-12.4%) |
| Dec 2016 | $214.50 M(+11.3%) | $214.50 M(-4.5%) |
| Sept 2016 | - | $224.60 M(-5.7%) |
| June 2016 | - | $238.10 M(+22.2%) |
| Mar 2016 | - | $194.80 M(+1.0%) |
| Dec 2015 | $192.80 M(+18.8%) | $192.80 M(+7.3%) |
| Sept 2015 | - | $179.64 M(+6.2%) |
| June 2015 | - | $169.21 M(+8.4%) |
| Mar 2015 | - | $156.15 M(-3.8%) |
| Dec 2014 | $162.29 M(+28.5%) | $162.29 M(+16.0%) |
| Sept 2014 | - | $139.90 M(-34.3%) |
| June 2014 | - | $212.90 M(+61.6%) |
| Mar 2014 | - | $131.77 M(+4.3%) |
| Dec 2013 | $126.30 M(+8.3%) | $126.30 M(-3.3%) |
| Sept 2013 | - | $130.64 M(-0.7%) |
| June 2013 | - | $131.56 M(+29.8%) |
| Mar 2013 | - | $101.35 M(-13.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $116.63 M(+31.5%) | $116.63 M(+7.0%) |
| Sept 2012 | - | $108.95 M(+10.5%) |
| June 2012 | - | $98.58 M(+10.6%) |
| Mar 2012 | - | $89.15 M(+0.5%) |
| Dec 2011 | $88.68 M(+20.3%) | $88.68 M(+1.5%) |
| Sept 2011 | - | $87.39 M(+5.9%) |
| June 2011 | - | $82.53 M(+26.2%) |
| Mar 2011 | - | $65.42 M(-11.2%) |
| Dec 2010 | $73.71 M(+45.6%) | $73.71 M(-2.5%) |
| Sept 2010 | - | $75.57 M(-9.5%) |
| June 2010 | - | $83.51 M(+39.6%) |
| Mar 2010 | - | $59.81 M(+18.2%) |
| Dec 2009 | $50.63 M(+78.8%) | $50.63 M(+10.9%) |
| Sept 2009 | - | $45.65 M(+32.8%) |
| June 2009 | - | $34.37 M(-30.4%) |
| Mar 2009 | - | $49.41 M(+74.5%) |
| Dec 2008 | $28.31 M(+10.4%) | $28.31 M(-14.4%) |
| Sept 2008 | - | $33.09 M(+9.7%) |
| June 2008 | - | $30.18 M(+15.6%) |
| Mar 2008 | - | $26.11 M(+1.8%) |
| Dec 2007 | $25.65 M(+14.3%) | $25.65 M(+1.6%) |
| Sept 2007 | - | $25.25 M(+8.7%) |
| June 2007 | - | $23.23 M(+22.2%) |
| Mar 2007 | - | $19.01 M(-15.3%) |
| Dec 2006 | $22.45 M(+61.8%) | $22.45 M(+26.2%) |
| Sept 2006 | - | $17.80 M(-0.8%) |
| June 2006 | - | $17.95 M(+22.9%) |
| Mar 2006 | - | $14.60 M(+5.2%) |
| Dec 2005 | $13.87 M(+0.9%) | $13.87 M(-13.1%) |
| Sept 2005 | - | $15.97 M(+3.4%) |
| June 2005 | - | $15.45 M(+12.6%) |
| Mar 2005 | - | $13.72 M(-0.2%) |
| Dec 2004 | $13.74 M(+35.4%) | $13.74 M(+27.3%) |
| Sept 2004 | - | $10.79 M(+11.2%) |
| June 2004 | - | $9.70 M(+27.1%) |
| Mar 2004 | - | $7.63 M(-24.8%) |
| Dec 2003 | $10.15 M(+5.2%) | $10.15 M(+15.4%) |
| Sept 2003 | - | $8.80 M(-13.0%) |
| June 2003 | - | $10.11 M(+4.2%) |
| Mar 2003 | - | $9.71 M(+0.6%) |
| Dec 2002 | $9.65 M(+564.5%) | $9.65 M(-17.4%) |
| Sept 2002 | - | $11.68 M(+10.3%) |
| June 2002 | - | $10.59 M(+498.5%) |
| Mar 2002 | - | $1.77 M(+21.8%) |
| Dec 2001 | $1.45 M | $1.45 M(-4.0%) |
| Sept 2001 | - | $1.51 M(-52.0%) |
| June 2001 | - | $3.15 M(+21.2%) |
| Mar 2001 | - | $2.60 M |
FAQ
- What is United Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for United Therapeutics?
- What is United Therapeutics annual accounts receivable year-on-year change?
- What is United Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for United Therapeutics?
- What is United Therapeutics quarterly accounts receivable year-on-year change?
What is United Therapeutics annual accounts receivable?
The current annual accounts receivable of UTHR is $278.90 M
What is the all time high annual accounts receivable for United Therapeutics?
United Therapeutics all-time high annual accounts receivable is $297.10 M
What is United Therapeutics annual accounts receivable year-on-year change?
Over the past year, UTHR annual accounts receivable has changed by +$58.50 M (+26.54%)
What is United Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of UTHR is $341.80 M
What is the all time high quarterly accounts receivable for United Therapeutics?
United Therapeutics all-time high quarterly accounts receivable is $341.80 M
What is United Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, UTHR quarterly accounts receivable has changed by +$83.20 M (+32.17%)